Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Link
http://link.springer.com/content/pdf/10.1007/s10620-019-05704-5.pdf
Reference11 articles.
1. Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. Dig Dis Sci. (Epub ahead of print). https://doi.org/10.1007/s10620-019-05617-3 .
2. Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an alpha4beta7 integrin antagonist for ulcerative colitis and Crohn’s disease. Ther Adv Chronic Dis. 2015;6:224–233.
3. Kim HP, Reed CC, Herfarth HH, Dellon ES. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16:1992–1994.
4. Schoepfer A, Blanchard C, Dawson H, et al. Eosinophilic esophagitis: latest insights from diagnosis to therapy. Ann N Y Acad Sci. 2018;1434:84–93.
5. Taft TH, Mutlu EA. The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16:1840–1841.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms;Cells;2023-10-18
2. Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy;Pharmaceutics;2023-09-21
3. Current state of biologics in treating eosinophilic esophagitis;Annals of Allergy, Asthma & Immunology;2023-01
4. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets;Frontiers in Physiology;2022-01-12
5. Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns;Journal of Neuroimmunology;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3